Benzinga··Vandana SinghRhythm Pharma's Obesity Drug Fails Primary Trial, Pivots to Next-Gen Candidates
Rhythm Pharmaceuticals' setmelanotide fails EMANATE Phase 3 primary endpoints for rare genetic obesity, sending stock down 4.98%. Company pivots to next-generation MC4R agonists.
RYTMbiotechclinical trial failure